世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

尿素サイクル障害治療市場 - 世界の産業規模、シェア、動向、機会、予測、2017-2027酵素欠損タイプ別(カルバミルリン酸合成酵素(CPS1)、N-アセチルグルタミン酸合成酵素(NAGS)、オルニチントランスカルバミラーゼ(OTC欠損)、アルギニノコハク酸合成酵素(AS)、アルギニノコハク酸リアーゼ(ALまたはASAリアーゼ)、アルギナーゼ(AG))、治療タイプ別(アミノ酸製剤、フェニル酪酸塩、安息香酸ナトリウム、その他)、投与経路別(経口/静脈)、流通チャネル別(病院薬局、小売薬局、オンライン薬局)、企業別、地域別


Urea Cycle Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027Segmented By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG)), By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others), By Route of Administration (Oral v/s Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Company, and By Region

世界の尿素サイクル障害治療市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されている。主な要因としては、尿素サイクル障害の有病率の増加、広範な研究開発が世界的な市場の成長を牽引しています。... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechSci Research
テックサイリサーチ
2023年8月1日 US$4,900
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
111 英語

 

サマリー

世界の尿素サイクル障害治療市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されている。主な要因としては、尿素サイクル障害の有病率の増加、広範な研究開発が世界的な市場の成長を牽引しています。尿素サイクル障害(UCD)は、肝周囲細胞で尿素サイクルを構成する遺伝子異常のグループである。市場の成長を支えるその他の要因としては、政府による研究開発活動への投資の増加、主要企業によるイニシアチブの増加、大衆の意識の高まり、より良い医療サービスの存在、革新的な診断アプローチの増加などが挙げられる。
人口における尿素サイクル障害の有病率の上昇
尿素サイクル障害の有病率の増加は、世界的な市場の成長を促進する可能性が高い。米国疾病予防管理センター(CDC)が発表した報告によると、尿素サイクル障害の予測発生率は出生8500人に1人である。多くの症例が未診断のままであり、障害を持つ新生児は完全な診断がつかないまま死亡するため、正確な数は不明である。乳幼児突然死症候群(SIDS)の症例の最大20%は、尿素サイクル障害のような先天性代謝異常の未診断に起因すると考えられており、尿素サイクル障害治療市場を刺激すると予想されている。
患者における取り組みと意識の高まり
過去数年にわたり、各国の政府や民間団体は、市場の成長を後押しするためにいくつかの措置を講じてきた。研究開発への多額の投資、認知度向上プログラムの増加、広範な研究活動や臨床試験、規制機関による承認の容易さといったイニシアチブの高まりが、市場を支える要因となっている。例えば、2017年にミード・ジョンソン・ニュートリション・カンパニー(MJN)はレキット・ベンキーザー・グループplc(RB)との合併を宣言した。RBの一部門となったミード・ジョンソンは、尿素サイクル障害の食事管理に使用されるEnfaとNutramigenをRBのコンシューマーヘルス・ポートフォリオに組み込み、世界的に認知されたブランドを獲得し、世界的な地位を強化した。同様に、2017年にHorizon Pharma plcは、尿素サイクル障害に苦しむ個人のためのイニシアチブであるUCD in Commonを立ち上げ、UCD患者、その家族、医療専門家に教育的、支援的、双方向的なリソースを提供している。
市場区分
世界の尿素サイクル障害治療市場は、酵素欠損タイプ、治療タイプ、投与経路、流通チャネル、企業ごとに区分される。酵素欠損タイプに基づくと、市場はカルバミルリン酸合成酵素(CPS1)、N-アセチルグルタミン酸合成酵素(NAGS)、オルニチントランスカルバミラーゼ(OTC欠損症)、アルギニノコハク酸合成酵素(AS)、アルギニノコハク酸リアーゼ(ALまたはASAリアーゼ)、アルギナーゼ(AG)に分けられる。治療薬の種類により、市場はアミノ酸製剤、フェニル酪酸塩、安息香酸ナトリウム、その他に分けられる。投与経路に基づき、市場は経口投与と静脈内投与に分けられる。流通チャネルでは、病院薬局、小売薬局、オンライン薬局に分けられる。国別では、米国は尿素サイクル疾患の患者数が増加していることから、予測期間において有利な市場になると予想される。
市場プレイヤー
Bausch Health Companies Inc.、Recordati Rare Diseases、Eurocept Pharmaceuticals Holding(Lucane Pharma SA)、Acer Therapeutics、Ultragenyx Pharmaceutical、Aeglea BioTherapeutics、Arcturus Therapeutics, Inc.、Orpharma Pty Ltd.、Selecta Biosciences, Inc.、Abbott Laboratories, Inc.などは、この市場で事業を展開している大手企業です。
報告書の範囲
本レポートでは、世界の尿素サイクル障害治療市場を、業界動向に加えて、以下のカテゴリーに分類しています:
- 尿素サイクル障害治療市場:酵素欠損タイプ別
o カルバミルリン酸合成酵素(CPS1)
o N-アセチルグルタミン酸合成酵素(NAGS)
o オルニチントランスカルバミラーゼ(OTC欠損症)
o アルギニノコハク酸合成酵素(AS)
o アルギニノコハク酸リアーゼ(ALまたはASAリアーゼ)
o アルギナーゼ(AG)
- 尿素サイクル障害治療市場、治療タイプ別
o アミノ酸製剤
o フェニル酪酸塩
o 安息香酸ナトリウム
o その他
- 尿素サイクル障害治療薬市場:投与経路別
o 経口剤
o 静注
- 尿素サイクル障害治療薬市場:流通経路別
o 病院薬局
o 小売薬局
o オンライン薬局
- 尿素サイクル障害治療市場:地域別
o 北米
 米国
 カナダ
 メキシコ
o アジア太平洋
 中国
 インド
 日本
 オーストラリア
 韓国
ヨーロッパ & CIS
 ドイツ
 フランス
 イギリス
 スペイン
 イタリア
o 南米
 ブラジル
 アルゼンチン
 コロンビア
o 中東・アフリカ
 南アフリカ
 サウジアラビア
 UAE
競争環境
企業プロフィール:尿素サイクル障害治療市場に参入している主要企業の詳細分析
利用可能なカスタマイズ:
TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。本レポートでは以下のカスタマイズが可能です:
企業情報
- 追加市場プレイヤー(最大5社)の詳細分析とプロファイリング

ページTOPに戻る


目次

1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on Global Urea Cycle Disorders Treatment Market
4. Voice of Customer
5. Executive Summary
6. Global Urea Cycle Disorders Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG))
6.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others)
6.2.3. By Route of Administration (Oral v/s Intravenous)
6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.5. By Company (2021)
6.2.6. By Region
6.3. Market Map
7. North America Urea Cycle Disorders Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Enzyme Deficiency Type
7.2.2. By Treatment Type
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Urea Cycle Disorders Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Enzyme Deficiency Type
7.3.1.2.2. By Treatment Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Mexico Urea Cycle Disorders Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Enzyme Deficiency Type
7.3.2.2.2. By Treatment Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Canada Urea Cycle Disorders Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Enzyme Deficiency Type
7.3.3.2.2. By Treatment Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
8. Europe Urea Cycle Disorders Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Enzyme Deficiency Type
8.2.2. By Treatment Type
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Urea Cycle Disorders Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Enzyme Deficiency Type
8.3.1.2.2. By Treatment Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Germany Urea Cycle Disorders Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Enzyme Deficiency Type
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Enzyme Deficiency Type
8.3.3.2.2. By Treatment Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. Italy Urea Cycle Disorders Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Enzyme Deficiency Type
8.3.4.2.2. By Treatment Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Spain Urea Cycle Disorders Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Enzyme Deficiency Type
8.3.5.2.2. By Treatment Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. Asia-Pacific Urea Cycle Disorders Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Enzyme Deficiency Type
9.2.2. By Treatment Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Urea Cycle Disorders Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Enzyme Deficiency Type
9.3.1.2.2. By Treatment Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. India Urea Cycle Disorders Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Enzyme Deficiency Type
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. Japan Urea Cycle Disorders Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Enzyme Deficiency Type
9.3.3.2.2. By Treatment Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
9.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Enzyme Deficiency Type
9.3.4.2.2. By Treatment Type
9.3.4.2.3. By Route of Administration
9.3.4.2.4. By Distribution Channel
9.3.5. Australia Urea Cycle Disorders Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Enzyme Deficiency Type
9.3.5.2.2. By Treatment Type
9.3.5.2.3. By Route of Administration
9.3.5.2.4. By Distribution Channel
10. South America Urea Cycle Disorders Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Enzyme Deficiency Type
10.2.2. By Treatment Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Enzyme Deficiency Type
10.3.1.2.2. By Treatment Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Argentina Urea Cycle Disorders Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Enzyme Deficiency Type
10.3.2.2.2. By Treatment Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Colombia Urea Cycle Disorders Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Enzyme Deficiency Type
10.3.3.2.2. By Treatment Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. Middle East and Africa Urea Cycle Disorders Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Enzyme Deficiency Type
11.2.2. By Treatment Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Urea Cycle Disorders Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Enzyme Deficiency Type
11.3.1.2.2. By Treatment Type
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Distribution Channel
11.3.2. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Enzyme Deficiency Type
11.3.2.2.2. By Treatment Type
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Distribution Channel
11.3.3. UAE Urea Cycle Disorders Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Enzyme Deficiency Type
11.3.3.2.2. By Treatment Type
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Bausch Health Companies Inc.
14.2. Recordati Rare Diseases
14.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
14.4. Acer Therapeutics
14.5. Ultragenyx Pharmaceutical
14.6. Aeglea BioTherapeutics
14.7. Arcturus Therapeutics, Inc.
14.8. Orpharma Pty Ltd.
14.9. Selecta Biosciences, Inc
14.10. Abbott Laboratories, Inc.
15. Strategic Recommendations

 

ページTOPに戻る


 

Summary

The global urea cycle disorders treatment market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the increasing prevalence of urea cycle disorder, and extensive research and development are driving the growth of the market globally. Urea cycle disorders (UCDs) are a group of genetic defects that constitute the urea cycle in the periportal liver cells. The other factors supporting the market's growth are rising investments in research and development activities by the government, increasing initiatives by key players, rising awareness among the masses, the presence of better healthcare services, and a growing number of innovative diagnostic approaches.
Rising Prevalence of urea cycle disorders among the Population
The growing prevalence of urea cycle disorders is likely to propel the growth of the market globally. According to reports published by the Centers for Disease Control and Prevention (CDC), the projected occurrence of urea cycle disorders is 1 in 8500 births. Owing to the many cases which remain undiagnosed and the newborns with the disorders die without a complete diagnosis; the exact numbers remain unknown. It is assumed that up to 20% of Sudden Infant Death Syndrome (SIDS) cases may be ascribed to an undiagnosed inborn error of metabolism, such as a urea cycle disorder which is anticipated to impel the urea cycle disorders treatment market.
Increasing Initiatives and Awareness Among Patients
Over the past few years, governments of different nations and private organizations have been taking several steps to bolster the growth of the market. Rising initiatives such as heavy investments in research and development, increase in awareness programs, extensive research activities and clinical trials, and ease in approvals by the regulatory bodies are the supporting factors for the market. For instance, in 2017, Mead Johnson Nutrition Company (MJN) declared its merger with Reckitt Benckiser Group plc (RB). Mead Johnson, now a division of RB, included its globally recognized brands, incorporating Enfa and Nutramigen, which are used in the dietary management of urea cycle disorder, to RB's consumer health portfolio, thus bolstering its position globally. Similarly, in 2017, Horizon Pharma plc launched UCD in Common, an initiative for individuals suffering from urea cycle disorder, to offer educational, supportive, and interactive resources to the patients residing with UCD, their families, and healthcare specialists.
Market Segmentation
The global urea cycle disorders treatment market is segmented into enzyme deficiency type, treatment type, route of administration, distribution channel, and company. Based on enzyme deficiency type, the market is divided into carbamyl phosphate synthetase (CPS1), N-acetyl glutamate synthetase (NAGS), ornithine transcarbamylase (OTC deficiency), argininosuccinic acid synthetase (AS), argininosuccinate lyase (AL or ASA lyase), and arginase (AG). Based on treatment type, the market is divided into amino acid formulas, phenylbutyrate, sodium benzoate, and others. Based on the route of administration, the market is divided into oral and intravenous. Based on distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of cases of urea cycle diseases in the country.
Market Players
Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories, Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global urea cycle disorders treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type:
o Carbamyl Phosphate Synthetase (CPS1)
o N-Acetylglutamate Synthetase (NAGS)
o Ornithine Transcarbamylase (OTC Deficiency)
o Argininosuccinic Acid Synthetase (AS)
o Argininosuccinate Lyase (AL or ASA Lyase)
o Arginase (AG)
• Urea Cycle Disorders Treatment Market, By Treatment Type:
o Amino Acid Formulas
o Phenylbutyrate
o Sodium Benzoate
o Others
• Urea Cycle Disorders Treatment Market, By Route of Administration:
o Oral
o Intravenous
• Urea Cycle Disorders Treatment Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Urea Cycle Disorders Treatment Market, By Region:
o North America
 United States
 Canada
 Mexico
o Asia-Pacific
 China
 India
 Japan
 Australia
 South Korea
o Europe & CIS
 Germany
 France
 United Kingdom
 Spain
 Italy
o South America
 Brazil
 Argentina
 Colombia
o Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Urea Cycle Disorders Treatment Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).



ページTOPに戻る


Table of Contents

1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on Global Urea Cycle Disorders Treatment Market
4. Voice of Customer
5. Executive Summary
6. Global Urea Cycle Disorders Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG))
6.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others)
6.2.3. By Route of Administration (Oral v/s Intravenous)
6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.5. By Company (2021)
6.2.6. By Region
6.3. Market Map
7. North America Urea Cycle Disorders Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Enzyme Deficiency Type
7.2.2. By Treatment Type
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Urea Cycle Disorders Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Enzyme Deficiency Type
7.3.1.2.2. By Treatment Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Mexico Urea Cycle Disorders Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Enzyme Deficiency Type
7.3.2.2.2. By Treatment Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Canada Urea Cycle Disorders Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Enzyme Deficiency Type
7.3.3.2.2. By Treatment Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
8. Europe Urea Cycle Disorders Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Enzyme Deficiency Type
8.2.2. By Treatment Type
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Urea Cycle Disorders Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Enzyme Deficiency Type
8.3.1.2.2. By Treatment Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Germany Urea Cycle Disorders Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Enzyme Deficiency Type
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Enzyme Deficiency Type
8.3.3.2.2. By Treatment Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. Italy Urea Cycle Disorders Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Enzyme Deficiency Type
8.3.4.2.2. By Treatment Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Spain Urea Cycle Disorders Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Enzyme Deficiency Type
8.3.5.2.2. By Treatment Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. Asia-Pacific Urea Cycle Disorders Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Enzyme Deficiency Type
9.2.2. By Treatment Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Urea Cycle Disorders Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Enzyme Deficiency Type
9.3.1.2.2. By Treatment Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. India Urea Cycle Disorders Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Enzyme Deficiency Type
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. Japan Urea Cycle Disorders Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Enzyme Deficiency Type
9.3.3.2.2. By Treatment Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
9.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Enzyme Deficiency Type
9.3.4.2.2. By Treatment Type
9.3.4.2.3. By Route of Administration
9.3.4.2.4. By Distribution Channel
9.3.5. Australia Urea Cycle Disorders Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Enzyme Deficiency Type
9.3.5.2.2. By Treatment Type
9.3.5.2.3. By Route of Administration
9.3.5.2.4. By Distribution Channel
10. South America Urea Cycle Disorders Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Enzyme Deficiency Type
10.2.2. By Treatment Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Enzyme Deficiency Type
10.3.1.2.2. By Treatment Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Argentina Urea Cycle Disorders Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Enzyme Deficiency Type
10.3.2.2.2. By Treatment Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Colombia Urea Cycle Disorders Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Enzyme Deficiency Type
10.3.3.2.2. By Treatment Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. Middle East and Africa Urea Cycle Disorders Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Enzyme Deficiency Type
11.2.2. By Treatment Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Urea Cycle Disorders Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Enzyme Deficiency Type
11.3.1.2.2. By Treatment Type
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Distribution Channel
11.3.2. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Enzyme Deficiency Type
11.3.2.2.2. By Treatment Type
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Distribution Channel
11.3.3. UAE Urea Cycle Disorders Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Enzyme Deficiency Type
11.3.3.2.2. By Treatment Type
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Bausch Health Companies Inc.
14.2. Recordati Rare Diseases
14.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
14.4. Acer Therapeutics
14.5. Ultragenyx Pharmaceutical
14.6. Aeglea BioTherapeutics
14.7. Arcturus Therapeutics, Inc.
14.8. Orpharma Pty Ltd.
14.9. Selecta Biosciences, Inc
14.10. Abbott Laboratories, Inc.
15. Strategic Recommendations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(その他)の最新刊レポート

TechSci Research 社の最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/07/12 10:27

160.11 円

174.44 円

209.47 円

ページTOPに戻る